Botulinum Toxin for Ocular Tics

Gilad Yahalom1,2,*, Achinoam Faust-Socher1, Hanna Strauss1, Sheera F. Lerman1,3, Sharon Hassin-Baer1,2 and Oren S. Cohen1,2

1The Parkinson Disease and Movement Disorders Clinic, Sagol Neuroscience Center, Chaim Sheba Medical Center, Tel-Hashomer, Israel
2Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3Department of Psychology, Ben Gurion University of the Negev, Beer Sheva, Israel

Abstract: Introduction: Onabotulin toxin A is an effective treatment for a variety of movement disorders; yet, results of efficacy in patients with medically-resistant tic disorders are insufficient. We aimed to assess the efficacy of Onabotulin toxin A in patients with ocular tics in an observational study.

Methods: Patients with ocular tics, regularly treated with Onabotulin toxin A injections at our clinic, were enrolled for 2 visits, one of which was for baseline assessment and a single injection session and the second -a follow-up visit one month after treatment for evaluation of outcome. The assessment tools consisted of a 10-minute videotape recording which was scored later by a blinded rater. The calculated ocular tic frequency was the primary end-point of this study. Secondary outcome measures consisted of additional items obtained from the video recording as well as the motor subset of the Yale Global Tic Severity Scale (YGTSS-M) and the Clinical Global Impression of change (CGI-C).

Results: Six patients were enrolled. Video recordings and rating of the ocular tics before and after treatment revealed a 37% reduction in mean tic frequency, a 2.18-fold prolongation of the time to the first tic following suppression and a reduction in tic frequency during and after suppression by 45% and 52%, respectively. The mean YGTSS-M decreased by 39%. Five patients reported an improvement in CGI-C while one reported no change.

Conclusions: In this observational study, Onabotulin toxin A was found to be an effective treatment for ocular tics, providing both subjective and objective benefit for a subset of patients.

Keywords: Botulinum toxin, efficacy, ocular tics, tic disorder.

INTRODUCTION AND BACKGROUND

A tic is a semi- or involuntary body movement or vocal sound that is sudden, rapid and repetitive [1]. It has a stereotyped but non-rhythmic character. The tic is preceded usually by a premonitory sensation or "urge" and is experienced as irresistible although it can be suppressed for a short period of time. Tics can be categorized as motor or vocal and as simple or complex [1].

Tics involving the eyelids or ocular muscles (ocular tics) are among the most common forms of motor tics. They may be part of transient or chronic tic disorders or part of Tourette syndrome (TS). The pathophysiology of tics is still not clear. Basal ganglia dysfunction was postulated as the main site of dysfunction while recent evidences indicate cerebellar involvement in tic generation [2].

Although some medications such as dopamine depletors, neuroleptics, benzodiazepines and alpha2-agonists are in use for tics relief, the efficacy of these medications is still questionable and the treatment is often limited by severe side effects including sedation, parkinsonism, tardive dyskinesia, hepatotoxicity and prolongation of QT-interval [3], that make their use in non-TS tic disorders unjustified.

Onabotulin toxin A is a potent neurotoxin that blocks neuromuscular transmission and when injected to the affected muscles, it is effective for a variety of movement disorders including dystonia [4] and spasticity [5]. Its efficacy in tic disorders was assessed in a small number of studies [6-9], which showed in most cases a beneficial effect.

In the present observational prospective study, we aimed to document both objective and subjective effects of Onabotulin toxin A injections for ocular tics.

MATERIALS AND METHODS

Between the years 2010- 2012, patients diagnosed by a movement disorder specialist at Sheba Medical Center as having ocular tics, and who were treated regularly by Onabotulin toxin A, were enrolled. All patients had failed on various oral therapies. The study was approved by the...
institutional review board and all patients signed an informed consent form prior to inclusion.

All patients had 2 visits: A baseline visit (visit 1), in which demographics and medical records were reviewed and Onabotulinum toxin A injection was administered; and a follow-up visit (visit 2) one month after treatment. The injected muscles included the orbicularis oculi (upper and lower eyelids), frontalis, corrugators and paranasal muscles and the exact sites and the doses were adjusted on an individual basis, depending on the location, the description and extent of the tics. The injection sites and doses were usually identical to the patient’s prior injection sessions, as these had been found previously to provide the best effect.

**Efficacy Evaluation**

In both visits patients had a 10-minute videotape recording of the face, including 5 minutes of baseline or neutral state, 3 minutes of voluntary attempt of tic suppression, and 2 minutes neutral state following suppression. The video recordings were assessed in a random order by a single rater (OC) blinded to the visit, for number of tics during rest period, and during and following suppression. In addition, the time to first tic following suppression was documented. The tic frequency during rest obtained from these recordings was the primary end-point of this study. Additionally, patients completed the motor subset of the Yale Global Tic Severity Scale (YGTSS-M). At visit 2, patients were asked to rate the Clinical Global Impression of Change (CGI-C) questionnaire and were inquired about side effects of the injections.

**Statistical Analysis**

Due to the small sample size, statistical analysis was not performed. Instead, we measured the proportional change in the outcome of the different scores at visit 2 versus baseline, as follows:

\[
\text{Proportional change} = \frac{\text{outcome visit 2} - \text{outcome at visit 1}}{\text{outcome visit 1}}
\]

**RESULTS**

Six patients were enrolled (3 males, age ± SD: 40.5 ± 15.3 years) and treated by injections of Onabotulinum toxin A to the muscles surrounding the eyes. Three patients had an isolated ocular tic disorder, 2 had mild TS, 1 patient suffered from tardive tics, and 1 patient had both cervical and ocular tics.

The mean total dose of Onabotulinum toxin A (Botox®, Allergan Pharmaceuticals, Irvine, California, USA) was 40.17 ± 11.2 IU (range 29-60 IU). The mean number of previous Onabotulinum toxin A treatment sessions prior to enrollment was 7.5 ± 3.2.

Measures of the ocular tics are presented in Table 1. The mean tic frequency during rest was averagely reduced by 37%. In addition the tic frequency decreased both during and after suppression by 45% and 52%, respectively, and the time to the first tic during suppression was prolonged by 2.18-fold. The YGTSS-M score was reduced by 39% (5 patients improved). Five patients reported an improvement on CGI-C while one reported no change.

**DISCUSSION**

In this small observational study of patients with ocular tics treated with Onabotulinum toxin A injections, a clinically significant objective and subjective benefit was evident as both reduction of tics frequency along with patient satisfaction were documented.

### Table 1. Rating of Ocular Tics before and after treatment with Botulinum toxin injections.

<table>
<thead>
<tr>
<th>Pt.</th>
<th>Gender/Age (years)</th>
<th>Tic frequency -rest (blinks/sec)</th>
<th>Change</th>
<th>Time to first tic -suppression (sec)</th>
<th>Change</th>
<th>Tic frequency -suppression (blinks/sec)</th>
<th>Change</th>
<th>Tic frequency -after suppression (blinks/sec)</th>
<th>Change</th>
<th>YGTSS-M</th>
<th>Change</th>
<th>CGI-C Pt.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>1</td>
<td>F/47</td>
<td></td>
<td>4.0</td>
<td>0.6</td>
<td></td>
<td>0.85</td>
<td>8.0</td>
<td>10.9</td>
<td>12.6</td>
<td>3.0</td>
<td>1.3</td>
<td>0.57</td>
</tr>
<tr>
<td>2</td>
<td>F/49</td>
<td></td>
<td>3.2</td>
<td>1.8</td>
<td></td>
<td>0.44</td>
<td>7.6</td>
<td>4.0</td>
<td>0.47</td>
<td>1.7</td>
<td>2.7</td>
<td>1.59</td>
</tr>
<tr>
<td>3</td>
<td>F/22</td>
<td></td>
<td>4.8</td>
<td>6.2</td>
<td></td>
<td>1.29</td>
<td>13</td>
<td>22</td>
<td>1.69</td>
<td>3.0</td>
<td>1.3</td>
<td>0.57</td>
</tr>
<tr>
<td>4</td>
<td>M/25</td>
<td></td>
<td>4.4</td>
<td>3.0</td>
<td></td>
<td>0.32</td>
<td>10</td>
<td>6.2</td>
<td>5.2</td>
<td>4.3</td>
<td>1.3</td>
<td>0.70</td>
</tr>
<tr>
<td>5*</td>
<td>M/38</td>
<td></td>
<td>43.4</td>
<td>5.2</td>
<td></td>
<td>0.88</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6*</td>
<td>M/62</td>
<td></td>
<td>53.8</td>
<td>25.4</td>
<td></td>
<td>0.53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Mean ±SD | 19.6± 24.5 | 7.0± 9.2 | 0.37 | 26.8± 32.9 | 58.3± 37.6 | 2.18 | 3.0± 1.1 | 1.6± 0.7 | 0.45 | 9.1± 3.2 | 4.4± 4.4 | 0.52 | 12.3± 7.5 | 3.9± 3.9 |

Abbreviation: Pt – patient; Pre – before treatment; Post – after treatment; YGTSS-M – Motor subscale of the Yale Global Tic Severity Scale; CGI-C – The Change in Clinical Global Improvement Scale, rated by the patient; + no change, + mild improvement, ++ moderate improvement, +++ very much improved.

*Patients who were only videotaped in rest (neutral state) due to technical problems.
Our positive results are in accordance with previous reports of treatment of various tics in patients with diverse tic disorders; Kwak et al. [6] assessed 35 patients (14 of whom had ocular tics) in an open label study and the patients favorably rated the treatment with Onabotulinum toxin A using a 0-4 simple scale, with a mean peak effect of 2.8. The study of Kwak et al. did not rate the different tics separately, thus the specific effect on ocular tics was lacking.

Marras et al. [7] conducted a randomized placebo-controlled study of Onabotulinum toxin A versus placebo injections including 18 patients with simple motor tics (10 of whom had ocular tics). Treatment response items were retrieved from videotape recording as well as several additional scales and the primary outcome measure was tic frequency during rest from the video recording. While Onabotulinum toxin A was effective in tic rate reduction (39% in treated patients vs. 5.8% increase in tics in the placebo group), it did not have a favorable effect on the patient general well-being, as expressed by the CGI-C patient questionnaire, the Shapiro Tourette Syndrome Severity Score and other scores, probably due to the impact of the remaining tics not targeted by the injections. The study of Marras et al. neither rated the different tics separately, thus the specific effect on ocular tics was lacking.

Patients included in our report were those complaining of one bothersome focal tic, involving the ocular area, for which they were seeking an effective treatment. Our sample could potentially be biased since it consists of those patients who were treated routinely, and were supposed to be satisfied from the treatment. None of our patients was naïve to Onabotulinum toxin A treatment. There is lack of information on the proportion of patients lost to follow up due to treatment failure.

We do not know what portion of patients with ocular tics may benefit from Onabotulinum toxin A injections and what the profile of responders is. This will have to be studied in a large group of Onabotulinum toxin A treatment-naïve subjects suffering from ocular tics in a randomized double-blind placebo-controlled study.

Nevertheless we have shown that a subset of these patients gain both an objective and a subjective improvement of their tics with this treatment. Others have shown that the premonitory urge decreases as well with these injections [6, 8].

CONCLUSION

As we are convinced that Onabotulinum toxin A injections are effective for ocular tics, and their safety profile is excellent in the hands of experienced physicians, this conservative focal treatment should be offered in the case of bothersome ocular tics possibly prior to offering oral medication, as the latter option commonly provides both limited efficacy and frequent side effects.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES